Quick Takeaways:
- Alveo Technologies and Royal GD have expanded their partnership to develop rapid molecular tests on the Alveo Sense platform for pathogens affecting swine and cattle, while expanding the existing poultry testing portfolio.
- The companies have already collaborated for three years, including 18 months of commercial deployment of their jointly developed on-farm avian influenza test.
- The expanded partnership aims to support earlier disease detection and faster intervention across livestock species, with new diagnostic applications expected to expand by 2027.
Why It Matters?
Alveo Technologies and Royal GD are deepening a three‑year partnership (with 18 months of commercial use of their on‑farm avian influenza test) to co‑develop rapid molecular assays on the Alveo Sense platform for additional swine and cattle pathogens and to broaden the poultry menu beyond avian flu. The move extends Alveo’s point‑of‑need molecular diagnostics from poultry into larger livestock segments, supporting earlier on‑farm detection and faster intervention in a veterinary diagnostics market projected to grow at roughly 9–10% CAGR through 2031, while giving Royal GD a differentiated, field‑deployable testing portfolio to offer producers and veterinarians ahead of planned product expansions by 2027.
Source: PRnewswire
